ArticleBMC ophthalmology2026
Clinical applications of the amniotic membrane in pediatric ocular pathology: a scoping review.
Article in BMC ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe amniotic membrane (AM), which is derived from the placenta and is composed of columnar epithelium, a basement membrane, and an avascular stroma, is commonly preserved through cryopreservation. Its biological properties-combining safety, versatility, and efficacy-have positioned it as an innovative therapeutic option in pediatric ophthalmology for multiple ocular pathologies.
objectiveTo explore the available evidence on the clinical applications of the AM in pediatric ocular pathologies. METHODOLOGY: A scoping review was conducted in accordance with the PRISMA guidelines, using databases such as PubMed, LILACS, Scopus, SciELO, and EBSCO, without date restrictions. Sixteen studies published between 2002 and 2025 were included, encompassing retrospective studies, cohort studies, case reports, and narrative reviews. The evidence was categorized into general benefits, benign neoplasms, surface defects, severe hypersensitivity, cryptophthalmos, ocular trauma, and glaucoma.
resultsThe reviewed studies demonstrated that AM, owing to its anti-inflammatory, antimicrobial, and antiangiogenic properties, is effective as a biological bandage in various pediatric ocular conditions. Its application promotes re-epithelialization, modulates inflammation, and improves healing. Nevertheless, further studies are needed to establish standardized protocols and validate their long-term effectiveness in this age group.
conclusionsThe use of the AM has shown promising results as a safe and effective intervention in pediatric ophthalmology, highlighting its therapeutic value in challenging, multifactorial clinical scenarios.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.